Thomas thanks for a good post. I do want to clarify a few things.
When you say they will drop the Hep C trial, are you referring to ChronTech or Ino? I think ChronTech will most likely drop the trial, because I cannot think of where they will get money from...
Ino is currently negotiating with big pharma for a partnership they hope to close by June. It is one of the major reasons for the last dilution.
While Ino does keep a fair R&D budget, they can easily coast for a while in that area, as they have a lot going on already. Also, most of the R&D is done by David Weiner and U Penn and is mostly covered by the university. So while their innovation is quite high, the R&D is quite low.
Using the ChronTech failure as a reason to proclaim Ino is no longer a viable business and will now fail is just plain silly.
Saying electroporation is the only revenue for the company is not accurate either. The company often has much higer revenue from its manufacturing drugs for other companies to use in their phase 1 and 2 trials. None of the revenue the company generates is very much right now. Both areas could be expanded.
I will start speculating now to address the multiple ways Ino has to get more money if needed.
Ino can easily license its electropoation technology to a major pharma. Ino can easily license or sell any of its current vaccines in development to another company.
Ino has the SynCon system which is what allows it to develop its many vaccines at such a rapid pace. It is entirely possible to licnese that platform to other companies for development or simple use.
I know the company has had multiple offers from multiple companies to do just that.
The company has other means to access non dilutive financing that few here seem to know about. The company has accessed such financing on multiple occasions, and it could if needed access that again. I am being deliberatly vage in this answer.
In a really dire situation, the compan could sell SynCon and or Cellectra, and the electroporation patent portfolio. Either property would be worth much more than the current market cap of the company. Again, I know the company has been approached in the past about such things.
That is just a quick off the top group of ideas. I know from the past that Joseph often comes up with ways that I simply cannot fathom until he does it.
The company could also apply for a line of credit like most companies have. Ino does not. Which is rare and in my opnion good.
Finally, I am glad you point out how tough biotech is. Too few people are saying that here. This is a very tough business. Be ware of investing in BioTech!!!!
AI
